항정신병약물 사용으로 인한 항파킨슨제 병용 현황 연구
Analysis of Antipsychotic Induced Concomitant Prescribing of Antiparkinson Agents in Korea
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background & Purpose: It is well known that Extrapyramidal symptoms (EPS) is induced by atypical antipsychotic agents less frequently than by typical antipsychotic agents. The purpose of this study was to evaluate differences in rates of the use of antiparkinson agent, most commonly prescribed for the management of EPS, between patients with atypical agents and those with typical agents. Methods: This cross-sectional study was conducted in a retrospective way with the Electronic Medical Record (EMR) of the 312 patients for whom the Antipsychotics were prescribed by the Psychiatry Department of the Inje University Ilsan Paik Hospital, from January of 2005 to February of 2011. They received either typical agents (N=15) or atypical agents (N=297) and those 2 groups were compared in terms of antiparkinson agent use. Also, we assessed the difference between individual atypical antipsychotic agents regarding antiparkinson agent use. Results: There was no significant difference in the rates of antiparkinson agent use between the two groups (the typical agent 13.33% vs. the atypical agent 9.76%, p = 0.6512). Meanwhile, the rates of antiparkinson agent use with aripiprazole versus quetiapine (aripirazole 25% vs. quetiapine 3.57%, p = 0.003) were significantly different,Also the rates of antiparkinson agent use with aripiprazole versus risperidone (aripiprazole 25% vs. risperidone 9.52%, p = 0.0216) had a statistical meaning. Conclusions: There was no significant difference in the rates of antiparkinson agent use between patients with atypical agents and those with typical agents. However the rate of antiparkinson agent use was significantly lower with aripiprazole compared with quetiapine or risperidone.
Abstract
Background & Purpose: It is well known that Extrapyramidal symptoms (EPS) is induced by atypical antipsychotic agents less frequently than by typical antipsychotic agents. The purpose of this study was to evaluate differences in rates of the use of antiparkinson agent, most commonly prescribed for the management of EPS, between patients with atypical agents and those with typical agents. Methods: This cross-sectional study was conducted in a retrospective way with the Electronic Medical Record (EMR) of the 312 patients for whom the Antipsychotics were prescribed by the Psychiatry Department of the Inje University Ilsan Paik Hospital, from January of 2005 to February of 2011. They received either typical agents (N=15) or atypical agents (N=297) and those 2 groups were compared in terms of antiparkinson agent use. Also, we assessed the difference between individual atypical antipsychotic agents regarding antiparkinson agent use. Results: There was no significant difference in the rates of antiparkinson agent use between the two groups (the typical agent 13.33% vs. the atypical agent 9.76%, p = 0.6512). Meanwhile, the rates of antiparkinson agent use with aripiprazole versus quetiapine (aripirazole 25% vs. quetiapine 3.57%, p = 0.003) were significantly different,Also the rates of antiparkinson agent use with aripiprazole versus risperidone (aripiprazole 25% vs. risperidone 9.52%, p = 0.0216) had a statistical meaning. Conclusions: There was no significant difference in the rates of antiparkinson agent use between patients with atypical agents and those with typical agents. However the rate of antiparkinson agent use was significantly lower with aripiprazole compared with quetiapine or risperidone.
참고문헌 (17)
- Jones PB, "Randomized Controlled Trial of the Effect on Quality of Life of Second vs First-Generation Antipsychotic Drugs in Schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS1)", Arch Gen Psychiatry, 63, pp.1079~1087 (2006)
- Casey DE, "Extrapyramidal syndromes; epidemiology, pathophysiology and the diagnostic dilemma", CNS Drugs, 5, pp.1~12 (1996)
- Miller CH, "The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics", J Clin Psychiatry, 59, pp.69~75 (1998)
- Fenton WS, "Determinants of medication compliance in schizophrenia: empirical and clinical findings", Schizophr Bull, 23, pp.637~651 (1997)
- Gervin M, "Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology", Eur Psychiatry, 14, pp.405~409 (1999)
- Leucht S, "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis", Lancet, 373, pp.31~41 (2009)
- Miller DD, "Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Extrapyramidal side-effects of antipsychotics in a randomised trial", Br J Psychiatry, 193, pp.279~288 (2008)
- Kane JM, "Akathisia: an updated review focusing on second-generation antipsychotics", J Clin Psychiatry, 70, pp.627~643 (2009)
- Ereshefsky L, "Clozapine: an atypical antipsychotic agent", Clin Pharm, 8, pp.691~709 (1989)
- Lieberman JA, "Clozapine: guidelines for clinical management", J Clin Psycchiatry, 50, pp.329~338 (1989)
- Barnes TR, "Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia", Int Clin Psychopharmacol, 13, pp.S49~S57 (1998)
- "Textbook of Psychiatry, 3th Edition", The American Psychiatric Publishing
- "Textbook of Psychopharmacology, 4th Edition. Chapter34. Drug to Treat Extrapyramidal Side Effects", The American Psychiatric Publishing
- Xiang YT, "Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009", Pharmacopsychiatry, 44, pp.114~118 (2011)
- De Hert M, "Anticholinergic use in hospitalised schizophrenic patients in Belgium", Psychiatry Res, 152, pp.165~173 (2007)
- Loga-Zec S, "Polypharmacy in the treatment of schizophrenic patients in three University Centers in the Federation of Bosnia and Herzegovina (F", BH), 2011, pp.23, 60~63
- Rummel-Kluge C, "Secondgeneration antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-tohead comparisons", Schizophr Bull, 38, pp.167~177 (2012)